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Substantial Urinary Concentrations of Material Resembling 13-CoreFragment of
Chorionic Gonadotropin /3-Subunit in Mid-Menstrual Cycle
Patrick Neven,”4 Ray K. lies,’ Ian Howes,2 Kiran Sharma,’ John H. Shepherd,1 Ray Edwards,2
William P. Collins,3 and Tim Chard’
We measured the day-to-day variations in concentrations
of p-core, luteinizing hormone (LH), and a-subunit in urine
during the menstrual cycle. The a-subunit concentrations
showed a pattern similar to that of the LH concentrations.
p-Core-like material was increased during and up to 3 to
4 days after the surge in urine LH. The urine LH concen-
tration was associated with the presence of a-core immu-
noreactivity during the urine LH peak. Chromatography
showed that, at the peak LH concentration and at 2 days
after the LH peak, p-core immunoreactivity could be ac-
counted for by the presence of a peptide of low molecular
mass similar to the p-core molecule of I,CG, but probably
originating from the degradation of LH. The prolonged
excretion of gonadotropin metabolites in the midcycle
must be considered when p-core is being assessed as a
tumor marker.
IndexIngTerms: luteinizinghormone tumor marker . varia-
tion, source of
The metabolism of circulating gonadotropins includes
degradation in the kidneys and excretion in urine. The
most abundant material relatedto human choriomc go-
nadotropin (hCG) in urine from pregnant women is a
fragment of the p-subunit known as p-core (1-3). A
similar protein of small molecular mass, which reacts in
assays for luteini.zing hormone (LH), is present in the
urine of nonpregnant pre- and postmenopausal women
(4). This cross-reactant probably results from degrada-
tion of the p-subunit of LH and is likely to have consid-
erable sequence homology with the p-core fragment of
hCG (5). Consequently, this p-LH core reacts in assays
directed against the p-core of hCG.
Measurement of urinary metaholites of p-hCG, espe-
daily of the core fragment, has been advocated as a
marker in some nontrophoblastic gynecological malignan-
cies (6-11). However, the presence of p-LH core iminuno-
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reactivity in the urine of normal postmenopausal women
must be considered when the concentration of /3-core-like
material is being evaluated in cancer patients (5).
There is little information on the amounts of urinary
gonadotropin metabolites excreted during the normal
menstrual cycle. Because gynecological malignancies
may occur during the premenopausal period, the pres-
ence of such metabolites in premenopausal women
would be highly relevant to an assessment of the clinical
value of urinary p-core as a cancer marker. We mea-
sured p-core-like activity in early-morning urine speci-
mens collected during the menstrual period, and present
evidence that urinary gonadotropin metabolites are
substantially increased during and after the midcycle
LII surge.
MaterIals and Methods
Samples
A total of 463 early-morning urine samples were col-
lected from 22 healthy premenopausal women (ages
19-29 years) from day 2 of a menstrual cycle up to the
following menses. The procedures followed were in ac-
cordance with the ethical standards of our institution’s
ethical committee. Sodium aside (1 g/L) was added to all
samples prior to storage at -20 #{176}C.All samples were
assayed for p-core-like material by RIA. The LH peak
(day 0) was measured by immunofluorometric assay
(IFMA) in each of the women by using samples from day
-1 to day +5, the periovulatory period. Samples from
the same period from nine randomly chosen cycles were
also assayed for free a-subunit (RIA) and by another LH
assay (immunoradiometric assay, IRMA).
Assays
p-Core immunoreactivity was measured by RIA with
a polyclonal sheep antiserum raised against purified
p-core from hCG (S504) and ‘251-labeled purified p-core
(12). Standards were calibrated against material pro-
vided by R. Wehmann and D. Blithe (NIH, Bethesda,
MD). This assay shows partial cross-reaction with intact
hCG (6.9%) and free p-hCG (18%), but negligible cross-
reactivity with LH, thyroid-stimulating hormone
(TSH), and follicle-stimulating hormone (FSH) (<0.7%).
LH was measured by two methods: a time-resolved
IFMA and an IRMA. The IFMA was performed in the
Diagnostics Research Unit of King’s College School of
Medicine and Dentistry. The assay is based on the direct
sandwich technique in which a polyclonal antibody is
used to capture the analyte and a europium-labeled
monoclonal antibody against the a-subunit is used to
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monitor the reaction. There is about 60% cross-reactiv-
ity for intact hCG, 15% for p-subunit of hCG, and 50%
for FSH, TSH, and the free a-subunit.
The polyclonal IRMA was provided by the North East
Thames Regional Immunoassay service. For this assay
the same aflinity-purifled polyclonal antibody as was
used in the IFMA was used for the capture and detection
of LH. Significant cross-reaction was found with hCG
(100%), free p-hCG (20%), and the a-subunit of the gly-
coprotein hormones (7%); negligible cross-reactivity oc-
curred with FSH and TSH (<0.2%).
a-Subunit was estimated by RIA with a polyclonal
rabbit antibody to a-hCG provided by J. G. Pierce
(UCLA School of Medicine, Los Angeles, CA). a-hCG
(CR123; NIH Center for Population Research) was used
as a standard and for the preparation of a labeled tracer.
There was a partial cross-reaction with intact hCG (4%),
LII (8%), and FSH (2%); cross-reaction with /3-hCG and
p-core was <1%.
Chromatography
Samples of urine (40 mL) from one woman, collected
on the day of the midcycle urine LH peak and 2 days
later, were concentrated by lyophilization after dialysis
against deionized distilled water. Samples (0.3 mL)
were loaded into a column (600 x 9 mm) of Sephadex
G-100 (Pharmacia, Uppsala, Sweden) and eluted with
0.05 molfL phosphate-buffered saline by ascending flow
at 6 mL/h at 4#{176}C.Fractions (0.7 mL) were collected and
assayed for p-core and LH (IRMA). The column was
calibrated by elution of Dextran Blue together with
‘251-labeled p-hCG and p-core.
Statistical Methods
The amounts of each analyte were not gaussian-dis-
tributed. Accordingly, the values were expressed as me-
dians and 95% confidence intervals. The Mann-Whit-
ney U-test was used to compare the relation between the
LH (IFMA) concentration and p-core activity in the
urine on the day of the LII peak. The Wilcoxon signed-
ranks test was used to assess the concentration differ-
ences of each analyte relative to the day before the urine
LII peak.
Results
In all subjects there was one major single peak of LH
as measured by IFMA. All results were analyzed in
relation to this day (day 0). An example of the findings
of all four assays in one cycle is shown in Figure 1. The
LH (IFMA) showed one distinct peak with a small rise 3
days later. a-Subunit showed a similar pattern. The
presence of p-core and LH (IRMA) coincided with the
LH surge but produced a major peak 3 days later.
Figure 2 shows the presence of p-core in early-morn-
ing urine samples in relation to the LII peak (IFMA) in
all 22 individual cycles, p-Core concentrations were
higher on days 0 to 4 than on other days (P <0.05;
Wilcoxon signed-ranks test). There was a difference (P
<0.05; Mann-Whitney U-test) in the LH (IFMA) con-
centration between the women who had measurable
p-core concentrations (n = 12) and the women with
<0.10 g/L p-core (n = 10) activity at the LH peak.
/3-Core concentrations during the LH surge in these 12
cycles ranged from 0.17 to 0.60 p.g/L (median 0.32 pgfL).
/3-Core concentrations after the urine LH peak ranged
from 0.34 to 0.95 pg/L (median 0.45 g/L). In 10 of these
12 cycles there was a separate peak of urine p-core
between 1 and 5 days after the urine LII surge.
In 10 cycles there was no p-core activity at all on the
day of the LH peak. Nine of these, however, had a peak
of p-core activity between 1 and 5 days after the urine
LH peak day. The concentrations at the peak in each
case ranged from 0.15 to 0.32 sgfL (median, 0.29 pg/L).
Figure 3 shows median concentrations for all four
assays in the nine cycles. Median p-core concentrations
were highest on the days after the LII peak. Median
concentrations as measured by LH (IRMA) were highest
on day 0 and remained high on days 1 to 5. The pattern
of a-subunit concentrations closely paralleled LII
(IFMA) immunoreactivity.
Chromatography of the concentrated urine (day 0)
showed an early peak corresponding to intact LII and a
later peak corresponding to p-core (Figure 4A). The
day-2 sample (Figure 4B) showed LH and p-core activity
only in the fractions containing metabolites of lower
molecular mass.
Discussion
Our finding that the excretion of /3-core-like material
continues for several days after the urine LH peak in
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Fig. 3. Median concentrations for all four assays in the nine cycles
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premenopausal women is important, because midcycle
urine p-core concentrations were often above the 95th
centile that we were using as a cutoff for the use of
/3-core as a tumor marker (0.36 g/L) (manuscript in
preparation). This finding weakens the value of (3-core
as a tumor marker for gynecological malignancies in
premenopausal women.
We regarded the IFMA as the “gold standard” for
urine LH. Identification of the materials present in
urine and their contribution to the results of a given
assay is not straightforward. The /3-core-like material
measured at day 0 in 12 of the 22 women might be due
to /3-core derived from LH or hCG, or to the cross-reac-
tion of intact LII or hCG in the p-core assay. The fact
that women without p-core activity on the LH-peak day
had lower concentrations of LH (IFMA) might support
the view that cross-reactivity occurs with intactLH.
However, the cross-reaction of intact LII in the p-core
assay is <0.7% (12). It is also possible that some of the
immunoreactivity on day 0 is related to intact hCG,
because specific assays for LII and hCG in serum
showed the presence of an hCG protein similar to LII
(13). These authors reported that hCG is produced in a
pulsatile fashion in all normal adults. In premenopausal
women, they found a midcycle ovulatory peak of intact
1ICG coincident with the LH peak; however, the molar
concentration of the hCG peak was much lower than
that of the LH peak. In support of the presence of p-core
material is the finding of a peak of immunoreactive
materialof low molecular mass in urine collected on day
0 (Figure 4A). Variation in the timing of the LH surge
between individual women and the variable duration of
the surge may explain why metabolites were present in
some subjects but not others.
The p-core immunoreactive material present in 19 of
the 22 women some days after the urine LH peak might
be LH- or hCG-derived metabolites. This p-core-like ma-
terial reacted in the LII IRMA, which does not recognize
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the p-core fragment of pregnancy. This supports the
view that it might be the p-core of LH, not hCG.
A second peak in urinary LH within 24 h of the initial
surge in urine LH, originally shown by Thomas and
Ferin (14), was attributed to the pulsatile nature of LH
secretion (15). Other authors have also reported a sec-
ondary, smaller, increase in urinary LH (16-18). Bei-
tins et a!. (4) reported the presence of LII, FSH, free
a-subunit, and an LH-/3 of smaller size in the urine of
normal premenopausal women throughout the men-
strual cycle, but did not comment on daily variation
relative to the LII peak.
There are three possible explanations for the observa-
tion that urine p-core-like material is maximal after the
day of peak urine LH: (a) There might be a continued
and increasing secretion of a core-like material related
to LH, with a peak in the luteal phase. (b) Metabolism
of gonadotropin in the kidneys might lead to prolonged
urinary excretion of core material from a slow-turnover
pool in the renal parenchyma. The disappearance rate of
both LH and hCG from serum follows a double exponen-
tial curve, with a first component reflecting clearance
from blood and a slow component from a pool of organs
involved in degradation (19). After administration of
hCG and its p-subunit to volunteers, the appearance of
core material in the urine is delayed for 12-24 h (20-
22). In our subjects, p-core-like activity was maximal at
days 1 to 5 after the urine LH peak. Cole et al. (23)
described a deactivation mechanism for hCG, leading
from hCG in the cell to p-core fragment in the urine.
p-Core fragment concentrations diminished more slowly
than hCG concentrations. A similar deactivation path-
way might exist for LII. (c) Cross-reaction might occur
with FSH, which appears in urine 1 to 4 days after the
peak in urine LII (16, 24). Further, FSH metabolites
could account for some of the core immunoreactivity.
The fact that urine 13-core concentrations are in-
creased for several days in the midcycle should be taken
into account in considering the value of p-core measure-
ments in premenopausal patients with cancer.
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